HALOHealthcare · BiotechnologyThe 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $105 — +6.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.4% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $92 → $93 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $115 |
| 7 Aug 2026 | Leerink Partners | Upgrade | Outperform | $83 → $110 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $96 → $105 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $95 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $96 → $93 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | Benchmark | Maintains | Buy | — |
| 19 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2025 | Goldman Sachs | Maintains | Neutral | — |
| 4 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 27 Oct 2025 | JP Morgan | Maintains | Neutral | — |
| 20 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HALO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 20% of US stocks
Cheaper than 2% of US stocks
Cheaper than 31% of US stocks
Higher than 86% of US stocks
Higher than 71% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 86% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Halozyme Therapeutics as an incredible growth stock, noting the company is well positioned to outperform the market due to above-average growth in its financials.
Why it matters — A HALO watcher would care because the report affirms the company's strong growth profile and market positioning.
A Zacks Investment Research article examines how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed relative to their sector so far this year, previewing their year-to-date stock comparisons. The report's headline asks whether HALO is outpacing its medical peers this year.
Why it matters — A HALO watcher would care because this piece directly compares Halozyme's year-to-date stock performance against both its sector and another stock, offering context on how the company is tracking relative to its peers.
Halozyme reported second-quarter earnings and revenues that beat estimates, driven by higher royalties and product sales. The company also raised its 2026 outlook, and its stock rose on the news.
Why it matters — A HALO watcher would care because the earnings beat and raised 2026 guidance signal stronger-than-expected revenue momentum from royalties and product sales.
Halozyme Therapeutics reported record second-quarter revenue and raised its full-year outlook. The company cited growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches, and revenue from newly signed collaboration agreements.
Why it matters — For Halozyme watchers, the record revenue and raised full-year outlook signal sustained strength in the ENHANZE platform and expanding collaboration-driven income.
Seeking Alpha published the transcript of Halozyme Therapeutics, Inc.'s Q2 2026 earnings call. The transcript covers the company's second-quarter 2026 financial results and related discussion.
Why it matters — HALO watchers would consult this transcript for management's official commentary on the company's Q2 2026 performance and outlook.
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $105, with estimates ranging from $70 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Halozyme Therapeutics, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +6.4% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $115 over the next 12 months.
Halozyme Therapeutics, Inc. returned +50.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why". Zacks Investment Research highlights Halozyme Therapeutics as an incredible growth stock, noting the company is well positioned to outperform the market due to above-average growth in its financials.
Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions. The company focuses on enhancing the administration of biologic and other injectable therapies through its proprietary ENHANZE drug delivery technology, built on the recombinant human hyaluronidase enzyme rHuPH20. This platform enables subcutaneous delivery of medicines that are traditionally given intravenously, aiming to reduce treatment time and ease the burden on patients across oncology and other therapeutic areas. Halozyme Therapeutics also develops, manufactures, and commercializes drug-device combination products that use advanced auto-injector technologies to improve convenience, reliability, and tolerability. Its current product portfolio includes Hylenex recombinant, a formulation of rHuPH20 used to facilitate subcutaneous fluid and drug administration, and XYOSTED, a subcutaneous auto-injector for testosterone replacement therapy. The company operates a hybrid model of proprietary products and partnered programs, licensing its technology to major pharmaceutical companies to support the delivery of emerging and established therapies. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics today plays a notable role in the global biotechnology and specialty pharmaceuticals market.
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com